S

M

SAUVEZIE , Mathieu

Last name: SAUVEZIE

First name: Mathieu

2019 (v1)

Journal article

Metadata-only

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Chiche, Edmond Bertoli, Sarah Rahme, Ramy

IntroductionCPX-351 is a liposomal formulation of cytarabine and daunorubicin packaged at a 5:1 molar ratio. This drug has recently been approved by FDA and EMEA for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML).The primary objective of this study was to analyze the efficacy of...

Uploaded on: December 3, 2022